6549 Stock Overview
A specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TaiwanJ Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$10.00 |
| 52 Week High | NT$19.10 |
| 52 Week Low | NT$9.60 |
| Beta | -0.42 |
| 11 Month Change | -2.44% |
| 3 Month Change | -4.76% |
| 1 Year Change | -23.66% |
| 33 Year Change | 0% |
| 5 Year Change | 1.21% |
| Change since IPO | -80.00% |
Recent News & Updates
Shareholder Returns
| 6549 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 1.6% |
| 1Y | -23.7% | 3.4% | 36.6% |
Return vs Industry: 6549 underperformed the TW Biotechs industry which returned 3.4% over the past year.
Return vs Market: 6549 underperformed the TW Market which returned 36.6% over the past year.
Price Volatility
| 6549 volatility | |
|---|---|
| 6549 Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6549 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6549's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 12 | Rich Yuan | www.taiwanj.com |
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis.
TaiwanJ Pharmaceuticals Co., Ltd. Fundamentals Summary
| 6549 fundamental statistics | |
|---|---|
| Market cap | NT$800.42m |
| Earnings (TTM) | -NT$27.75m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-28.9x
P/E RatioIs 6549 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6549 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$27.76m |
| Earnings | -NT$27.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6549 perform over the long term?
See historical performance and comparison